Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Last trade$0.1729
Day change+$0.007 (+4.22%)
Day range$0.153 – $0.184
Volume1,667,247
Market cap$15M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.62M
Price / earnings
—
Price / book
0.5×
Price / sales
—
EV / sales
—
EV / EBITDA
0.41×
Profitability
Earnings per share
-$0.48
Return on assets
-120.12%
Return on equity
-141.55%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.59×
Quick ratio
6.59×
Cash ratio
6.26×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$34.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CNTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.24M
$2.44M
$2.33M
$1.96M
$1.89M
$1.93M
$2.07M
$1.79M
Research and development
$5.72M
$12.53M
$7.02M
$11.84M
$8.72M
$7.83M
$3.46M
$2.52M
Total operating expenses
$7.96M
$14.97M
$9.34M
$13.8M
$10.61M
$9.76M
$5.53M
$4.31M
Operating income
-$7.96M
-$14.97M
-$9.34M
-$13.8M
-$10.61M
-$9.76M
-$5.53M
-$4.31M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$7.62M
-$14.56M
-$8.68M
-$13.03M
-$9.69M
-$8.83M
-$4.58M
-$3.34M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.62M
-$14.56M
-$8.68M
-$13.03M
-$9.69M
-$8.83M
-$4.58M
-$3.34M
Net income attributable to common shareholders
-$7.62M
-$14.56M
-$8.68M
-$13.03M
-$9.69M
-$8.83M
-$4.58M
-$3.34M
EBITDA
-$7.95M
-$14.96M
-$9.34M
-$13.8M
-$10.61M
-$9.75M
-$5.53M
-$4.31M
Basic earnings per share
-$0.08
-$0.15
-$0.09
-$0.14
-$0.10
-$0.09
-$0.05
-$0.04
Diluted earnings per share
-$0.08
-$0.15
-$0.09
-$0.14
-$0.10
-$0.09
-$0.05
-$0.04
Recent news
Company coverage with links to the original publishers.
Stock markets declined following a higher-than-expected CPI inflation report. Three companies were added to the Zacks Rank #5 (Strong Sell) list due to downward earnings estimate revisions: Cadiz Inc., Cerenome Inc., and Context Therapeutics Inc.
Three companies have been added to the Zacks Rank #5 (Strong Sell) list due to significant downward revisions in earnings estimates over the past 60 days. ATS Corporation, an industrial automation company, saw a 6.7% downward revision. Cango Inc., a bitcoin mining company, experienced an 18.2% downward revision. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, faced a 15% downward revision.
Step Pharma has appointed Dr. Karen Smith as Chief Medical Officer, bringing over 25 years of pharmaceutical experience to advance their CTPS1 inhibitor dencatistat across multiple cancer and blood disorder indications.
Context Therapeutics Inc. announced the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, for CLDN6-positive gynecologic and testicular cancers. The company expects to share initial data in the first half of 2026.
The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.